Cargando…
Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study
BACKGROUND: Norepinephrine (NE) is recommended for children and full-term neonates (born at >37 gestational weeks) with septic shock. Meanwhile, data on the effectiveness of NE in preterm neonates are still limited. This study aimed to evaluate the clinical efficacy of NE in preterm neonates with...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106054/ https://www.ncbi.nlm.nih.gov/pubmed/37045542 http://dx.doi.org/10.1136/bmjpo-2022-001804 |
_version_ | 1785026340938842112 |
---|---|
author | Lu, Pei Sun, Yifan Gong, Xiaohui Li, Zhiling Hong, Wenchao |
author_facet | Lu, Pei Sun, Yifan Gong, Xiaohui Li, Zhiling Hong, Wenchao |
author_sort | Lu, Pei |
collection | PubMed |
description | BACKGROUND: Norepinephrine (NE) is recommended for children and full-term neonates (born at >37 gestational weeks) with septic shock. Meanwhile, data on the effectiveness of NE in preterm neonates are still limited. This study aimed to evaluate the clinical efficacy of NE in preterm neonates with dopamine-resistant shock compared with that in full-term neonates. METHODS: This was a single-centre, retrospective (January 2010–December 2020) cohort study of neonates with persistent shock despite adequate fluid resuscitation and dopamine or dobutamine administration at ≥10 μg/kg/min. Medical records of neonates treated with NE were retrospectively reviewed to collect respiratory and haemodynamic parameters and results of arterial blood gas (ABG) tests before and 8 hours after NE infusion. The effectiveness of NE was assessed using changes in clinical parameters and multiple regression models for mortality among subgroups of preterm and full-term neonates. RESULTS: Ninety-two neonates (76% preterm) who received NE infusion were included in the study. NE infusion was started after a median of 7 hours (IQR 2–19 hours) after shock onset. Among the preterm neonates, the maximum dose of NE infusion was 0.5 (IQR 0.3–1.0) µg/kg/min with a median duration of 45 (IQR 24.0–84.5) hours. Haemodynamic dysfunction was ameliorated with increased blood pressure, decreased heart rate and improved ABG results. Preterm neonates with septic shock tended to have a reduced response to NE; however, preterm neonates with persistent pulmonary hypertension of the newborn tended to have a better response. Thirty-four (37%) neonates died in our cohort. The timing, dose and duration of NE use were not associated with neonatal mortality. CONCLUSIONS: Although using NE effectively improves clinical parameters in preterm neonates with dopamine-resistant shock, our study is underpowered to identify the association between NE infusion and mortality in preterm neonates with dopamine-resistant shock. |
format | Online Article Text |
id | pubmed-10106054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-101060542023-04-17 Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study Lu, Pei Sun, Yifan Gong, Xiaohui Li, Zhiling Hong, Wenchao BMJ Paediatr Open Neonatology BACKGROUND: Norepinephrine (NE) is recommended for children and full-term neonates (born at >37 gestational weeks) with septic shock. Meanwhile, data on the effectiveness of NE in preterm neonates are still limited. This study aimed to evaluate the clinical efficacy of NE in preterm neonates with dopamine-resistant shock compared with that in full-term neonates. METHODS: This was a single-centre, retrospective (January 2010–December 2020) cohort study of neonates with persistent shock despite adequate fluid resuscitation and dopamine or dobutamine administration at ≥10 μg/kg/min. Medical records of neonates treated with NE were retrospectively reviewed to collect respiratory and haemodynamic parameters and results of arterial blood gas (ABG) tests before and 8 hours after NE infusion. The effectiveness of NE was assessed using changes in clinical parameters and multiple regression models for mortality among subgroups of preterm and full-term neonates. RESULTS: Ninety-two neonates (76% preterm) who received NE infusion were included in the study. NE infusion was started after a median of 7 hours (IQR 2–19 hours) after shock onset. Among the preterm neonates, the maximum dose of NE infusion was 0.5 (IQR 0.3–1.0) µg/kg/min with a median duration of 45 (IQR 24.0–84.5) hours. Haemodynamic dysfunction was ameliorated with increased blood pressure, decreased heart rate and improved ABG results. Preterm neonates with septic shock tended to have a reduced response to NE; however, preterm neonates with persistent pulmonary hypertension of the newborn tended to have a better response. Thirty-four (37%) neonates died in our cohort. The timing, dose and duration of NE use were not associated with neonatal mortality. CONCLUSIONS: Although using NE effectively improves clinical parameters in preterm neonates with dopamine-resistant shock, our study is underpowered to identify the association between NE infusion and mortality in preterm neonates with dopamine-resistant shock. BMJ Publishing Group 2023-04-12 /pmc/articles/PMC10106054/ /pubmed/37045542 http://dx.doi.org/10.1136/bmjpo-2022-001804 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Neonatology Lu, Pei Sun, Yifan Gong, Xiaohui Li, Zhiling Hong, Wenchao Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study |
title | Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study |
title_full | Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study |
title_fullStr | Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study |
title_full_unstemmed | Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study |
title_short | Use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study |
title_sort | use of norepinephrine in preterm neonates with dopamine-resistant shock: a retrospective single-centre cross-sectional study |
topic | Neonatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106054/ https://www.ncbi.nlm.nih.gov/pubmed/37045542 http://dx.doi.org/10.1136/bmjpo-2022-001804 |
work_keys_str_mv | AT lupei useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy AT sunyifan useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy AT gongxiaohui useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy AT lizhiling useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy AT hongwenchao useofnorepinephrineinpretermneonateswithdopamineresistantshockaretrospectivesinglecentrecrosssectionalstudy |